Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.

ABSTRACT:

Background

Licensed systemic treatment options for platinum-sensitive recurrent ovarian cancer are platinum-based chemotherapy and maintenance treatment with bevacizumab and poly (ADP-ribose) polymerase inhibitors. For platinum-resistant disease, several non-platinum options are available. We aimed to assess the clinical benefit of these treatments according to the European Society of Medical Oncology (ESMO)-Magnitude of Clinical Benefit Scale (MCBS).

Materials and methods

A PubMed search was carried out including all studies evaluating systemic treatment of recurrent epithelial ovarian cancer, from 1990 onwards. Randomised trials with an adequate comparator and design showing a statistically significant benefit of the study arm were independently scored by two blinded obser

SUBMITTER: Broekman KE 

PROVIDER: S-EPMC8358417 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature